Why GM is reviving the Bolt, the best-selling EV it almost discontinued

Why GM is reviving the Bolt, the best-selling EV it almost discontinued


General Motors CEO Mary Barra unveiled the Chevrolet Bolt electric vehicle during the 2016 Consumer Electronics Show in Las Vegas.

Patrick T. Fallon | Bloomberg | Getty Images

General Motors surprised investors — and electric vehicle fans — when it said in July that the little Chevrolet Bolt EV will be revamped, rather than killed off entirely at the end of 2023 as originally planned.

During GM’s earnings call Tuesday, CEO Mary Barra shared more details on the thinking behind the decision to keep the Bolt around while giving some hints as to what Bolt fans can expect when the revamped EV goes on sale.

Barra said GM had originally planned to launch a series of newly designed EVs in entry-level segments at a total cost of around $5 billion. But given the popularity of the current Bolt — 2023 is already the model’s best year ever for sales — it made sense to revamp the existing car instead.

Read more: UAW expands strike to crucial GM SUV plant

“By leveraging the best attributes of today’s Bolt EV as well as Ultium, our latest software, and NACS, we will deliver an even better driving charging and ownership experience with a vehicle we know customers love,” Barra said. “In the process, we are saving billions in capital and engineering expense, delivering a significantly cost improved battery pack using purchased LFP cells.”

Launched in late 2016 and originally aimed at the ride-sharing market, the Bolt had never sold as well as GM had originally hoped. But a series of price cuts, the addition of a roomier crossover-like “EUV” variant in 2021 and American consumers’ steadily growing interest in EVs combined to give the Bolt a sales surge in what was supposed to be its final years.

That sales surge is a big part of why GM decided to keep the Bolt around. Sales were up more than 50% in 2022, to just over 38,000 Bolts. This year’s sales have already topped that number, with almost 50,000 Bolts sold through the end of September.

To be clear, the Bolt will be on hiatus for a while. GM still plans to end production of the current Bolt at its Michigan factory at the end of this year, and it hasn’t yet said when the revamped model will go on sale — or where it’ll be made. The Bolt’s current factory in Michigan will be retooled to make electric versions of GM’s Chevrolet Silverado and GMC Sierra pickup trucks.

But with durable and relatively inexpensive lithium-iron phosphate battery cells, GM’s improved Ultium platform and latest software and NACS charging ports that will allow it to use Tesla’s Supercharger network, the new Bolt looks set to continue to win new buyers.

“We’re getting to market at least two years faster, and our unit costs will be substantially lower,” Barra said.

Don’t miss these CNBC PRO stories:



Source

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored
Business

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored

In this photo illustration Hantavirus samples are seen in Ankara, Turkiye on May 6, 2026. Arman Onal | Anadolu | Getty Images The U.S. Centers for Disease Control and Prevention said there are no hantavirus cases in the country as of Thursday, as it monitors 41 people for the virus. The agency said the risk […]

Read More
These three artworks could sell for 0 million each next week as May auctions begin
Business

These three artworks could sell for $100 million each next week as May auctions begin

A large-scale Jackson Pollock drip painting titled, “Number 7A, 1948.” Crystal Lau | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Nearly $2 billion worth of art will come up […]

Read More
Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data
Business

Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses. […]

Read More